Uniqure NV Total Cash From Operating Activities Over Time
| QURE Stock | USD 5.05 0.31 5.78% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Uniqure NV Performance and Uniqure NV Correlation. Uniqure |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Uniqure NV. If investors know Uniqure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Uniqure NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.18) | Earnings Share (5.92) | Revenue Per Share 0.575 | Quarterly Revenue Growth 3.594 | Return On Assets (0.17) |
The market value of Uniqure NV is measured differently than its book value, which is the value of Uniqure that is recorded on the company's balance sheet. Investors also form their own opinion of Uniqure NV's value that differs from its market value or its book value, called intrinsic value, which is Uniqure NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Uniqure NV's market value can be influenced by many factors that don't directly affect Uniqure NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Uniqure NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if Uniqure NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Uniqure NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Cash From Operating Activities Analysis
Compare Uniqure NV and related stocks such as Rocket Pharmaceuticals, Rhythm Pharmaceuticals, and Solid Biosciences LLC Total Cash From Operating Activities Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RCKT | (6.9 M) | (6.9 M) | (6.9 M) | (6.5 M) | (9.7 M) | (17.4 M) | (37.3 M) | (26.1 M) | (53.8 M) | (64.7 M) | (74.6 M) | (121.2 M) | (178.1 M) | (194.9 M) | (185.2 M) |
| RYTM | (17.8 M) | (17.8 M) | (17.8 M) | (19.2 M) | (7.5 M) | (7 M) | (23.2 M) | (29.5 M) | (62.1 M) | (122.8 M) | (122 M) | (146 M) | (173.4 M) | (136.2 M) | (129.3 M) |
| SLDB | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (20.1 M) | (43.2 M) | (70.2 M) | (92.7 M) | (56.6 M) | (77.8 M) | (98 M) | (94.2 M) | (98.9 M) |
| MGTX | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (18.1 M) | (58.9 M) | 20 M | (64 M) | (10.5 M) | (73.1 M) | (105.4 M) | (100.1 M) |
| TERN | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (66.2 M) | (29.8 M) | (41.8 M) | (49.1 M) | (67.7 M) | (71.1 M) |
| ABOS | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (7.5 M) | (18 M) | (35.2 M) | (43.1 M) | (40.9 M) |
| INZY | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (18.8 M) | (36 M) | (48.2 M) | (57.8 M) | (70.7 M) | (67.1 M) |
| XFOR | (10.8 M) | (10.8 M) | (10.8 M) | (10.8 M) | (10.8 M) | (10.8 M) | (21.6 M) | (27.9 M) | (40.9 M) | (48.1 M) | (58.8 M) | (70.9 M) | (77.1 M) | (96.5 M) | (91.7 M) |
| PCVX | (15 K) | (15 K) | (15 K) | (15 K) | (15 K) | (15 K) | (15 K) | (15 K) | (30.5 M) | (47.1 M) | (46.6 M) | (121.4 M) | (170.6 M) | (296.8 M) | (282 M) |
| LRMR | (28.2 M) | (28.2 M) | (28.2 M) | (28.2 M) | (28.2 M) | (59.6 M) | (52 M) | (43.8 M) | (51.5 M) | (22.7 M) | (42.2 M) | (42.1 M) | (27.6 M) | (33.5 M) | (35.1 M) |
| SNDX | (9.3 M) | (9.3 M) | (9.3 M) | (7.3 M) | (14.4 M) | (2.4 M) | (35.2 M) | (47.4 M) | (68.5 M) | (50.6 M) | (71.3 M) | 29.1 M | (133.7 M) | (160.6 M) | (152.6 M) |
| MRUS | (9.6 M) | (9.6 M) | (9.6 M) | (9.6 M) | (17.7 M) | (25.2 M) | (27.1 M) | (44.9 M) | (46.3 M) | (63 M) | (79.9 M) | (59.6 M) | (149.9 M) | (142.2 M) | (135.1 M) |
| STRO | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (37.1 M) | 12.7 M | (65 M) | (67.8 M) | (81.7 M) | 3.5 M | (111.6 M) | (106 M) |
| KNSA | (21.9 M) | (21.9 M) | (21.9 M) | (21.9 M) | (21.9 M) | (21.9 M) | (21.9 M) | (50.2 M) | (81 M) | (158.4 M) | (136.5 M) | (126.3 M) | 5.8 M | 13.3 M | 14 M |
| DAWN | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (4.5 M) | (13.5 M) | (48.5 M) | (109.9 M) | (146.9 M) | (139.5 M) |
| GPCR | (14.3 K) | (14.3 K) | (14.3 K) | (14.3 K) | (14.3 K) | (14.3 K) | (14.3 K) | (14.3 K) | (14.3 K) | (14.3 K) | (14.3 K) | (32.2 K) | (46.1 M) | (79.4 M) | (75.4 M) |
| PHAT | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (1 M) | (36.5 M) | (69.7 M) | (148.6 M) | (146.5 M) | (137.6 M) | (144.5 M) |
| RGNX | (3 M) | (3 M) | (3 M) | (3 M) | (2.4 M) | (22.5 M) | (48.6 M) | (58 M) | 104.6 M | (107.7 M) | (54.1 M) | 218.9 M | (207.5 M) | (218.4 M) | (207.5 M) |
| REPL | (7.1 M) | (7.1 M) | (7.1 M) | (7.1 M) | (7.1 M) | (7.1 M) | (7.1 M) | (16 M) | (25.4 M) | (60.6 M) | (61.4 M) | (82.2 M) | (128.1 M) | (185.5 M) | (176.2 M) |
| RNA | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | (9.7 M) | 2.5 M | (37.1 M) | (94.8 M) | (136.3 M) | (119.1 M) | (113.1 M) |
| PTGX | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (14.4 M) | (30 M) | 3.9 M | (49.9 M) | (41.5 M) | (72.5 M) | (107.9 M) | (108.1 M) | (70.2 M) | (73.7 M) |
Uniqure NV and related stocks such as Rocket Pharmaceuticals, Rhythm Pharmaceuticals, and Solid Biosciences LLC Total Cash From Operating Activities description
My Equities
My Current Equities and Potential Positions
| Uniqure NV | QURE |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Netherlands |
| Exchange | NASDAQ Exchange |
USD 5.05
Additional Information and Resources on Investing in Uniqure Stock
When determining whether Uniqure NV is a strong investment it is important to analyze Uniqure NV's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Uniqure NV's future performance. For an informed investment choice regarding Uniqure Stock, refer to the following important reports:Check out Uniqure NV Performance and Uniqure NV Correlation. For information on how to trade Uniqure Stock refer to our How to Trade Uniqure Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Uniqure NV technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.